Aplisol Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global tuberculosis burden, public health screening initiatives, occupational exposure testing, low cost diagnostic access, established ppd testing protocols.

The growth in the forecast period can be attributed to renewed tb surveillance efforts, migration related screening needs, public health funding growth, early infection detection focus, expanded preventive care programs. Major trends in the forecast period include continued use of tuberculosis skin testing, public health screening programs, hospital and clinic based tb surveillance, focus on latent tb detection, occupational health testing demand.

The increasing prevalence of tuberculosis (TB) is expected to drive the growth of the aplisol market in the coming years. Tuberculosis (TB) is an infectious bacterial disease primarily affecting the lungs, caused by Mycobacterium tuberculosis, and it can spread to other parts of the body if not properly treated. The growing burden of tuberculosis is attributed to factors such as the emergence of drug-resistant strains, HIV co-infection, unfavorable socioeconomic conditions, rising global travel, underreporting within healthcare systems, and delays in treatment due to social stigma. Aplisol plays a critical role in tuberculosis diagnosis, as it is used in the Mantoux tuberculin skin test (TST), a widely used method for identifying both latent and active TB infections. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, total TB cases in the United Kingdom were reported at 4,380 in 2022 and increased by 10.7% to reach 4,850 in 2023. Therefore, the rising prevalence of tuberculosis (TB) is driving the growth of the aplisol market.

The increase in healthcare expenditure is expected to support the growth of the aplisol market going forward. Healthcare expenditure refers to the overall financial resources allocated to medical services, healthcare infrastructure, pharmaceuticals, and related healthcare activities. Rising healthcare expenditure is driven by factors such as an aging population, the growing incidence of chronic and lifestyle-related diseases, advancements in medical technology, and expanded access to healthcare services. Aplisol, used as a tuberculin skin test for tuberculosis diagnosis, contributes to healthcare spending through costs associated with testing, diagnostic procedures, and follow-up care among high-risk populations. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with a growth rate of 0.9% in 2022. In addition, total long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, the rise in healthcare expenditure is driving the growth of the aplisol market.

In April 2024, Endo Inc., a US-based pharmaceutical company, acquired Endo International plc for an undisclosed amount. Through this acquisition, Endo Inc. seeks to expand its product portfolio and strengthen its pipeline with innovative drug candidates. Endo International plc is a US-based pharmaceutical company specializing in branded specialty pharmaceuticals.

Major companies operating in the aplisol market are JHP Pharmaceuticals LLC.

North America was the largest region in the aplisol market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aplisol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aplisol market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the aplisol market by increasing costs associated with biologic reagent production and diagnostic distribution materials. These effects are most visible in public health programs and clinical testing facilities across developing regions. Higher import duties have influenced procurement budgets for mass screening initiatives. Logistics timelines have also been affected by regulatory import controls. At the same time, tariffs are supporting local diagnostic manufacturing and improving public health supply continuity.

The aplisol market research report is one of a series of new reports that provides aplisol market statistics, including aplisol industry global market size, regional shares, competitors with a aplisol market share, detailed aplisol market segments, market trends and opportunities, and any further data you may need to thrive in the aplisol industry. This aplisol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aplisol is a purified protein derivative (PPD) skin test used to identify tuberculosis (TB) infection. It is administered intradermally to evaluate the body’s immune response to antigens from Mycobacterium tuberculosis. A positive reaction suggests possible exposure to TB, though additional diagnostic tests are needed to confirm active disease.

The primary indication types for aplisol include tuberculosis testing and use in BCG-vaccinated individuals. Tuberculosis (TB) testing involves diagnostic methods used to detect infection with Mycobacterium tuberculosis, the bacterium responsible for TB. The product is distributed through hospitals, clinics, and pharmacies and is used by adult, geriatric, and pediatric populations.

The aplisol market consists of sales of TST kits, Aplisol solutions, diagnostic reagents, and TST injection devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.